Imlifidase

Name: Imlifidase in Kidney transplantation in highly sensitized patients: IgG-cleaving enzyme therapy
Published: 2026-09-14T15:39:06-04:00

Kidney transplantation in highly sensitized patients

Manufacturer: Hansa Biopharma
Regulatory submission: BLA submitted December 2025
Launch: Anticipated in the first quarter of 2027
Last updated: September 19, 2026

Section

Product information and disease description Place of product in therapy Approaches to treatment Current treatment options and standard of care

IgG-cleaving enzyme therapy

2 evidence topics · 3 sources

French consensus guidelines: patient selection

“cPRA ≥ 98%, ≤ 65-year of age, ≥ 3 years on the waiting list, and a low risk of biopsy-related complications.” (opens the source at this quote in a new tab)

European Delphi consensus on sensitized kidney-transplant recipients

“imlifidase might be considered for deceased kidney transplantation in selected patients for whom there are no other treatment options” (opens the source at this quote in a new tab)